Anti-cancer drug combinations approved by US FDA from 2011 to 2021: main design features of clinical trials and role of pharmacokinetics Salvador FudioAlvaro SellersRubin Lubomirov Review Article 27 August 2022 Pages: 285 - 299
Population pharmacokinetics of cisplatin in small cell lung cancer patients guided with informative priors Jurij Aguiar ZdovcMihaela VaupotičIztok Grabnar Original Article 20 August 2022 Pages: 301 - 313
Physiologically based pharmacokinetic modeling of ponatinib to describe drug–drug interactions in patients with cancer Tomoko O. MoritaKazuhiko Hanada Original Article 23 August 2022 Pages: 315 - 323
Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults Yizhe ChenKen OgasawaraGopal Krishna Original Article Open access 24 August 2022 Pages: 325 - 334
A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors C. MassardP. A. CassierS. Pant Original Article 28 August 2022 Pages: 335 - 344
Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole Aniruddha S. KarveJanki M. DesaiPankaj B. Desai Original Article 01 September 2022 Pages: 345 - 356
Absorption, metabolism and excretion of [14C]-sotorasib in healthy male subjects: characterization of metabolites and a minor albumin-sotorasib conjugate Irene VuuUpendra P. DahalBrett Houk Original Article 05 September 2022 Pages: 357 - 367
Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1 Yulia VugmeysterAna-Marija GrisicAkash Khandelwal Original Article Open access 06 September 2022 Pages: 369 - 379